The Drug Born from a Wildflower That is Quietly Reshaping Modern Medicine

The 60-Year-Old Drug That Scientists Keep Finding New Reasons to Love

A humble pill born from a flowering plant has quietly reshaped modern medicine over six decades. It controls blood sugar for millions of people worldwide and is now being studied for everything from aging to fertility. Could this old drug have more tricks left to reveal?

For more health and wellness information check out my YouTube Channel: https://www.youtube.com/@MyLongevityExperiment

From A Wildflower To A World-Changing Drug

Metformin’s story begins not in a laboratory but in a plant, Galega officinalis, also known as goat’s rue or French lilac, which served as a traditional herbal medicine in medieval Europe. For centuries, this plant was used to treat symptoms we now associate with diabetes, including excessive thirst and the need to urinate frequently. By the late 1910s, it was found to be rich in the compound guanidine, which was discovered to lower blood glucose levels. Springer + 2

The first physician to formally report metformin’s use in treating diabetes was the French doctor Jean Sterne, who published his findings in 1957. Despite this, metformin received limited attention early on, as it was considered less potent than other glucose-lowering biguanides at the time.

The drug’s reputation was further clouded by the association of related compounds, phenformin and buformin, with a dangerous buildup of lactic acid in the blood, leading to their withdrawal from several markets. Metformin didn’t receive approval from the U.S. Food and Drug Administration as a diabetes treatment until 1994. Springer + 2

Large clinical trials ultimately confirmed what many clinicians had suspected. Metformin was not only effective at lowering glucose, the body’s main form of sugar, but also at reducing diabetes-related complications, and it went on to become the primary treatment for type 2 diabetes across much of the world.

How Metformin Works Inside Your Body

Metformin belongs to a class of drugs known as biguanides. Unlike many other diabetes medications, it lowers blood sugar without increasing insulin secretion, which prevents dangerously low blood glucose levels. ScienceInsights

Its first and most important action is reducing the amount of glucose produced by the liver. In type 2 diabetes, the liver often produces excessive glucose through a process called hepatic gluconeogenesis, contributing to high fasting blood sugar levels. Metformin acts on liver cells to suppress this overproduction. It also reduces how much glucose is absorbed from food in the gut, and improves the way muscles take up glucose from the bloodstream. ScienceInsights

Metformin activates AMP-activated protein kinase, commonly known as AMPK, a major cellular regulator of lipid and glucose metabolism. When AMPK is switched on, the liver’s production of new glucose is reduced and tissues such as muscle are encouraged to take up and use more glucose. Unlike sulfonylureas, metformin does not promote weight gain, and it does not cause hyperinsulinemia. PubMed CentralPubMed Central

Beyond Diabetes: Promise And Limits

Metformin’s strong track record has made it a natural candidate for research into conditions far beyond blood sugar control, though the evidence remains uneven.

One well-established off-label application, meaning a drug is prescribed for a condition it has not been formally approved to treat, is polycystic ovary syndrome, or PCOS. PCOS is an endocrinopathy characterized by increased resistance to insulin, and metformin is one of the longest-established oral insulin-sensitizing agents available.

In women who are not pregnant, metformin improves insulin resistance, menstrual regularity, and androgen levels, particularly in those with obesity or insulin resistance, and may enhance fertility when combined with other treatments.

By improving how the body responds to insulin, the drug can help reduce the elevated androgen levels that disrupt ovulation and contribute to irregular or absent periods. Annals of Translational MedicineWiley Online Library

Metformin has also attracted significant interest for its possible effects on aging and longevity. Preliminary studies indicate that the drug can slow the aging process by improving insulin responsiveness, exerting antioxidant effects, and enhancing vascular health. A 2024 study published in the journal Cell evaluated the gero-protective effects of metformin in a rigorous 40-month study involving monkeys.

The results highlighted a significant slowing of aging indicators, notably a roughly six-year regression in brain aging. Despite these intriguing early findings, there is still no conclusive evidence that metformin slows aging in humans, and it is not approved for that purpose. Oxford AcademicThe Medical Advisor

Research has suggested that metformin may carry neuroprotective effects, with studies from Taiwan confirming that its use can reduce the risk of dementia. The decreased risk was consistently observed across both genders and different age groups, and the protection appeared to grow with longer duration of use.

An ongoing 18-month, double-blind, placebo-controlled trial, known as the Metformin in Alzheimer’s Dementia Prevention study, is investigating the protective effects of doses up to 2,000 mg per day, with results expected in 2027. However, large-scale, long-term clinical trials are still needed before any firm conclusions can be drawn about metformin’s role in preventing dementia and other neurodegenerative diseases. PubMed Centralnih

What You Need To Know About Side Effects

Metformin is generally well tolerated, but like all medicines it carries risks, and medical oversight matters.

The most common reactions are gastrointestinal, including nausea, stomach discomfort, diarrhea, changes in taste, and reduced appetite. Stomach problems occur in roughly 15 to 25% of people when they first start taking metformin. These often improve over time or when people switch to slow-release formulations that deliver the drug more gradually, and taking metformin with food can also help. clinicaltrials

A recognized concern with long-term use is vitamin B12 deficiency, which has been observed repeatedly in people with type 2 diabetes taking metformin. The effect appears to result from decreased gastrointestinal absorption of vitamin B12. Updated product information for medicines containing metformin now notes that vitamin B12 deficiency is a common adverse drug reaction, potentially affecting up to one in ten people who take it.

Over time, low vitamin B12 can lead to anemia, where the body lacks enough healthy red blood cells to carry oxygen properly, as well as peripheral neuropathy, a form of nerve damage in the hands or feet that can cause tingling, numbness, or weakness. PubMed CentralHero

A rare but more serious adverse effect is lactic acidosis, a dangerous buildup of lactic acid in the blood. Risk factors include conditions that increase lactate production, such as severe infections, severe liver or kidney disease, recent surgery, or any condition causing low oxygen delivery to tissues.

This is why regular monitoring of kidney and liver function is important, and healthcare professionals may advise pausing metformin before certain medical procedures or during periods of serious illness. PubMed Central

A Shifting Landscape In Diabetes Care

For decades, the standard approach was straightforward: start with metformin. In 2026, however, the National Institute for Health and Care Excellence updated its guidelines for type 2 diabetes in a significant way. The new NICE guidance recommends that most people with type 2 diabetes should now be offered metformin along with an SGLT-2 inhibitor from the very start of treatment. Healthcare-management

NICE noted that research has shown SGLT-2 inhibitors not only control blood sugar but actively protect the heart and kidneys, which is particularly important because heart disease is the leading cause of death in people with type 2 diabetes. NICE estimated that these changes could prevent around 17,000 deaths over three years across the UK.

SGLT-2 inhibitors had previously been underprescribed to women, older people, and Black patients, and the revised recommendations include provisions to monitor treatment access and address these disparities. The Pharmaceutical Journal + 2

That shift does not mean metformin has been sidelined. It remains a cornerstone of diabetes care, and NICE now suggests that people with type 2 diabetes without pertinent comorbidities be treated with modified-release metformin and an SGLT-2 inhibitor as their first-line treatment. The landscape is evolving, with treatment increasingly tailored to each individual’s health profile. Medical Dialogues

Metformin may have been around for six decades, but it continues to find its place in modern medicine. Affordable, reliable, and still revealing new dimensions of its potential, it stands as proof that the most enduring medicines are not always the newest ones, but the ones that keep earning their place.